Efficacy and safety of desensitization to allopurinol following cutaneous reactions

Arthritis and Rheumatism

Volumn 44, Issue 1, 2001, Pages 231-238

  Fam, Adel G ^a,c   Dunne, Shelly M ^b   Iazzetta, John ^a   Paton, Thomas W ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO EAST GENERAL HOSPITAL   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GOUT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RASH; SYSTEMATIC DESENSITIZATION; UREMIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLOPURINOL; DESENSITIZATION, IMMUNOLOGIC; DRUG ERUPTIONS; FEMALE; GOUT SUPPRESSANTS; HUMANS; MALE; MIDDLE AGED;

EID: 0035147111     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200101)44:1<231::AID-ANR30>3.0.CO;2-7     Document Type: Article

References (54)

1. The development of allopurinol
2. Excess of ampicillin rashes associated with allopurinol or hyperuricemia
3. Acute adverse reactions attributed to allopurinol in hospitalized patients
4. Allopurinol in the treatment of gout
5. Therapy in gout
6. Drug challenge and desensitization protocols
7. Sulphasalazine in rheumatoid arthritis: Desensitizing the patient with a skin rash
8. Trimethoprim/sulphamethoxazole incremental dosage regimen in human immunodeficiency virus-infected persons
9. Ciprofloxacin desensitization in a patient with cystic fibrosis
10. Desensitization to allopurinol in patients with gout and cutaneous reactions
11. Desensitization in a patient with chronic renal disease and severe allergy to allopurinol
12. Allopurinol hypersensitivity in a patient with severe, chronic, tophaceous gout
13. Allopurinol desensitization
14. Desensitization to allopurinol
15. Desensitization to allopurinol: A cautionary tale
16. Desensitization to allopurinol
17. Oral desensitization in patients with chronic tophaceous gout and allopurinol hypersensitivity
18. Allopurinol sensitivity in a patient with chronic tophaceous gout: Success of intravenous desensitization after failure of oral desensitization
19. Desensitization to allopurinol in a patient with previous failed desensitization
20. Familial hypersensitivity to allopurinol with subsequent desensitization
21. Successful oral desensitization in a patient with fixed eruption from allopurinol
22. Successful desensitization for treatment of a fixed drug eruption to allopurinol
23. Successful desensitization of a fixed drug eruption caused by allopurinol
24. Reinstitution of allopurinol therapy for gouty arthritis after cutaneous reactions
25. Efficacy and safety of desensitization to allopurinol following cutaneous reactions
26. Severe allopurinol toxicity: Description and guidelines for prevention in patients with renal insufficiency
27. The allopurinol hypersensitivity syndrome: Unnecessary morbidity and mortality
28. Allopurinol hypersensitivity syndrome: A review
29. HLA and allopurinol drug eruption
30. Some adverse reactions to allopurinol may be mediated by lymphocyte reactivity to oxypurinol
31. Cell-mediated immunity in allopurinol-induced hypersensitivity
32. Recurrent renal failure associated with hypersensitivity to allopurinol
33. The diagnostic role of the in vitro drug-induced interferon-γ release test in Stevens-Johnson syndrome
34. A survey of current prescribing practices of antiinflammatory and urate lowering drugs in gouty arthritis in the Province of Ontario
35. Evaluation of allopurinol use in patients with gout
36. Strategies and controversies in the treatment of gout and hyperuricemia
37. The management of gout
38. Effective management of gout: An analogy
39. Sulfinpyrazone induced uric acid urolithiasis with renal failure
40. Tumor lysis syndrome: Pathogenesis and management
41. Oxypurinol therapy in allopurinol-allergic patients
42. Allergic reaction to allopurinol with cross-reactivity to oxypurinol
43. Oxipurinol therapy in allopurinol-sensitive patients
44. Urate-oxidase prophylaxis of uric acid-induced renal damage in childhood leukemia
45. Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies
46. Urate oxydase for gouty arthritis in cardiac transplant recipients
47. Advances in the management of malignancy-associated hyperuricemia
48. Generation of cDNA probes directed by amino acid sequence: Cloning of urate oxidase
49. Excellent uricosuric efficacy of benzbromarone in cyclosporine-A-treated renal transplant patients: A prospective study
50. How should we treat tophaceous gout in patients with allopurmol hypersensitivity?
51. Treatment of chronic gout in patients with renal function impairment: An open, randomized, actively controlled study
52. Efficacy of allopurinol and benzbromarone for the control of hyperuricemia: A pathogenic approach to the treatment of primary chronic gout
53. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis
54. Severe adverse cutaneous reactions to drugs